Biocon’s arm inks MoU with MEM for Graduate Program & Talent Management

14 Sep 2012 Evaluate

Biocon India’s wholly owned subsidiary - Biocon Sdn Bhd, Malaysia and Manipal Education Malaysia (MEM), have entered into a Memorandum of Understanding (MoU) to collaborate for the development of human capital for the Biotechnology industry in Malaysia.

The MoU outlines the creation of an Internship Programme and Graduate Employment Programme for the admission of MIU’s students and graduates to Biocon’s Malaysia facility for training and employment. Through the MoU, Manipal International University’s (MIU) and Biocon will also be collaborating in the development of specialised training and skills enhancement to ensure that graduates from relevant disciplines are equipped and ready for entry into Biocon Malaysia. The MoU further provides for MEM to conduct employee training programmes at Biocon Malaysia facility.

Biocon, India's largest biotechnology company is a fully-integrated, innovation-driven healthcare enterprise with strategic focus on biopharmaceuticals and research services. The company is developing its manufacturing and R&D facility in Iskandar Malaysia, Johor with an investment of over RM500 million, which will be operational in 2014. Together with its team of over 6000 employees Biocon delivers affordable solutions to partners and customers in over 75 countries across the globe.

Manipal Education Malaysia (MEM) provides a suite of education facilities and services. It is the parent company of Manipal International University (MIU). MEM provides a suite of education facilities and services. Its flagship project is the Manipal International University (MIU). MIU’s interim campus is in Kelana Jaya whilst its 140 acre campus, costing over RM650 million is being developed in Nilai, Negeri Sembilan. The Nilai campus will be operational by the end of this year.

Biocon is Asia’s leading R&D based Biotechnology Company. It produces anti-diabetic agents like Acarbose, Pioglitazone, Repaglinides and Rosiglitazone. In the biological segment, it produces Insulin, Erythropoietin (EPO), Filgrastim (GCSF), Streptokinase and Monoclonal Antibodies.

Biocon Share Price

321.15 2.35 (0.74%)
30-Apr-2025 10:35 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1830.30
Dr. Reddys Lab 1187.15
Cipla 1557.75
Lupin 2103.20
Zydus Lifesciences 896.20
View more..
© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.
×
Please wait your portfolio is updating...